Avastin (bevacizumab)


Approval Status
Approved July 2009

Treatment for
renal cell carcinoma

Possible similar drugs

Urology & Kidneys , Cancer & Oncology

Avastin (bevacizumab) is a humanized antibody to vascular endothelial growth factor (VEGF).

Avastin is specifically indicated for the treatment of metastatic renal cell carcinoma in combination with interferon alfa.

Avastin is supplied as a solution for intravenous administration. The recommended initial dose of the drug for renal cell carcinoma is 10 mg/kg every 2 weeks in combination with interferon alfa.

FDA Approval
The FDA approval of Avastin for renal cell carcinoma was based on a multicenter, randomized, double-blind, international study comparing Avastin plus interferon alfa 2a (IFN- a2a) versus placebo plus IFN-a2a. The trial enrolled 649 patients who had undergone a nephrectomy were randomized (1:1) to receive either Avastin (10 mg/kg IV infusion every 2 weeks; n = 327) or placebo (IV every 2 weeks; n = 322) in combination with IFN-a2a (9 MIU subcutaneously three times weekly, for a maximum of 52 weeks). The subjects were treated until disease progression or unacceptable toxicity. The main outcome measure of the study was investigator-assessed progression free survival (PFS). Secondary outcome measures were overall response rate (ORR) and overall survival (OS). PFS was statistically significantly prolonged among patients receiving Avastin plus IFN-a2a compared to those receiving IFN-a2a alone; median PFS was 10.2 months vs. 5.4 months (p-value<0.0001). Among the 595 subjects with measureable disease, ORR was also significantly higher (30% vs. 12% (p < 0.0001). There was no improvement in OS based on the final analysis conducted after 444 deaths, with a median OS of 23 months in the Avastin plus IFN-a2a arm and 21 months in the IFN-a2a plus placebo arm.

Adverse events associated with the use of Avastin may include, but are not limited to, the following:

  • epistaxis
  • headache
  • hypertension
  • rhinitis
  • proteinuria
  • taste alteration
  • dry skin
  • rectal hemorrhage
  • lacrimation disorder
  • back pain
  • exfoliative dermatitis

Avastin (bevacizumab) is a humanized antibody to vascular endothelial growth factor (VEGF). It binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis.

For additional information regarding Avastin or renal cell carcinoma, please visit the Avastin web page.
Avastin (bevacizumab) Drug Information

The Avastin (bevacizumab) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top